Altre lingue Avacta Group Plc

Azioni

AVCT

GB00BYYW9G87

Tempo differito London S.E. Altri mercati azionari 09:01:29 18/04/2024			Variaz. 5gg	Var. 1 gen.
49,53 ^GBX	-0,45%		-5,33%	-57,34%

10/04	Transcript : Avacta Group Plc - Special Call
09/04	Avacta Group plc riferisce i dati dello studio clinico di Fase 1 di AVA6000 in corso al meeting annuale dell'AACR	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses	10/04
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	09/04
Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update	05/04
Avacta : Glossary	05/04
Avacta : Research and Development Spotlight Series – Episode 1	27/03
Avacta doses third patient in drug conjugate trial for tumour tissue	21/03
Avacta shareholders give AGM go-ahead to issue new shares	18/03
Avacta Group - Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be presented in a Poster at the American Association of Cancer Research Annual Meeting on April 9, 2024	07/03
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024	05/03
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	05/03
Avacta Group Upsizes Share Placement Amid Strong Investor Demand	29/02
Avacta increases placing size to GBP26 million thanks to strong demand	29/02
AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise	29/02
Avacta plans fundraise to fund clinical development	28/02
Avacta says new head of R&D Coughlin brings "deep expertise"	19/01
Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer	19/01
Avacta Group plc - Appointment of Chief Business Officer	20/12
Appointment of Chief Business Officer	19/12
Avacta taps biopharma veteran as Therapeutics business chief	19/12
Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division	19/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Avacta Group Plc

Azioni

AVCT

GB00BYYW9G87

Altre lingue

Filtri